Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER vs AMCILL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PHOXILLUM B22K 4/0 is a peritoneal dialysis solution containing bicarbonate/lactate as buffer. It corrects electrolyte imbalances, removes waste products (e.g., urea, creatinine) via diffusion and ultrafiltration across the peritoneal membrane. Bicarbonate helps correct metabolic acidosis.
Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Peritoneal dialysis for patients with end-stage renal disease,Correction of fluid and electrolyte imbalances,Correction of metabolic acidosis
Infections of the respiratory tract,Infections of the genitourinary tract,Meningitis,Septicemia,Endocarditis,Gastrointestinal infections,Prophylaxis of bacterial endocarditis
Intravenous infusion of 4 mmol/kg potassium phosphate per 24 hours, administered at a rate not exceeding 10 mmol/hour as part of total parenteral nutrition; typical adult dose: 30-40 mmol potassium phosphate per day.
250-500 mg orally every 8 hours or 500 mg every 12 hours; for severe infections, up to 1 g every 6 hours intravenously.
Terminal elimination half-life is approximately 0.5–1 hour in patients with normal renal function. In end-stage renal disease (ESRD), half-life extends to 6–8 hours, requiring dose adjustment.
1-1.5 hours in normal renal function; prolonged to 7-10 hours in anuria.
Bicarbonate and lactate are metabolized in the liver and kidneys. Lactate is converted to bicarbonate via hepatic gluconeogenesis and the Cori cycle.
Partially metabolized by hydrolysis; primarily excreted unchanged in urine via renal tubular secretion and glomerular filtration.
Renal: 100% (proximal tubular secretion and glomerular filtration). Biliary/fecal: negligible (<1%).
Renal: 60-80% unchanged; biliary: less than 10%; fecal: small amount.
Approximately 10–20% bound to albumin. Binding is low and clinically insignificant.
20% bound, primarily to albumin.
Volume of distribution is 0.2–0.3 L/kg (10–20 L in adults), approximating extracellular fluid volume. This small Vd is consistent with limited tissue penetration.
0.3 L/kg; indicates distribution into extracellular fluid.
Intravenous: 100% (only route of administration).
Oral: 50-70% (variable, reduced by food); IM: nearly 100%.
Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73m²) due to risk of hyperphosphatemia and hyperkalemia. In mild to moderate impairment (e GFR 30-89): reduce dose by 25-50% and monitor serum potassium and phosphate levels.
For Cr Cl 30-50 m L/min: administer every 12 hours; for Cr Cl 10-29 m L/min: administer every 18-24 hours; for Cr Cl <10 m L/min: administer every 24 hours.
No specific dose adjustment recommended for Child-Pugh class A or B. For Child-Pugh class C: use with caution and consider reducing dose by 25% due to potential for altered phosphate metabolism and encephalopathy risk.
No specific adjustments recommended for Child-Pugh A or B; use caution in severe hepatic impairment (Child-Pugh C) with monitoring.
Dose based on body weight: 1-2 mmol/kg/day of potassium phosphate intravenously as part of parenteral nutrition, with infusion rate not exceeding 0.5 mmol/kg/hour. Maximum daily dose: 4 mmol/kg.
Children >1 month: 25-50 mg/kg/day orally divided every 8 hours; for severe infections, up to 100 mg/kg/day IV divided every 6 hours. Maximum dose: 2 g/day.
Start at lower end of dosage range (e.g., 20-30 mmol/day) due to age-related renal function decline. Monitor renal function and serum electrolytes closely; adjust dose based on creatinine clearance.
No specific dose adjustment required; monitor renal function and adjust based on creatinine clearance.
None.
No FDA black box warning.
Peritonitis risk,Catheter-related infections,Fluid and electrolyte disturbances,Metabolic alkalosis (with high bicarbonate levels),Hypokalemia or hyperkalemia,Peritoneal membrane failure
Hypersensitivity reactions including anaphylaxis,Clostridioides difficile-associated diarrhea,Superinfection,Risk of seizures with high doses or renal impairment,Use caution in patients with mononucleosis (high risk of rash)
Hypersensitivity to any component,Pre-existing severe metabolic alkalosis,Documented peritoneal membrane failure,Abdominal or peritoneal defects (e.g., hernias, fistulas),Uncorrected mechanical defects in peritoneal cavity
Hypersensitivity to ampicillin, penicillins, or any component of the formulation,Infections caused by beta-lactamase-producing organisms
No direct food interactions, but dietary intake of potassium, calcium, and phosphorus must be managed per clinical guidelines during CRRT. Avoid high-potassium foods (e.g., bananas, oranges, potatoes) unless potassium supplementation is adjusted accordingly.
Food does not significantly affect absorption; may be taken with or without meals. Avoid alcohol: may increase risk of disulfiram-like reaction (rare).
No well-controlled studies in pregnant women. Animal reproduction studies not conducted. Potassium phosphate is essential for fetal development; however, hyperphosphatemia or electrolyte imbalances may pose risks. First trimester: theoretical risk of teratogenicity only with severe maternal hyperphosphatemia. Second/third trimesters: risks include fetal hyperphosphatemia, hypocalcemia, and potential soft tissue calcification. Use only if clearly needed.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. First trimester: Not associated with major birth defects. Second and third trimesters: Use only if clearly needed; potential for altered gut flora and diarrhea in neonate.
Potassium phosphate is present in human milk at levels consistent with physiological requirements. Milk-to-plasma ratio not established. Exogenous phosphate is rapidly absorbed and may cause hyperphosphatemia in the infant at high maternal doses. Caution advised; monitor infant for signs of hyperphosphatemia (e.g., hypocalcemia, tetany).
Ampicillin is excreted in breast milk in low concentrations (M/P ratio approximately 0.2). Compatible with breastfeeding; monitor infant for diarrhea or rash.
Physiologic increase in plasma volume and glomerular filtration rate in pregnancy may increase phosphate clearance, potentially requiring higher doses to maintain therapeutic levels. However, individualize dosing based on serum phosphate monitoring. No standard dose modification; adjust per clinical response and lab values.
Increased renal clearance during pregnancy may require higher doses to maintain therapeutic levels. Standard dosing is usually adequate for most indications; consider monitoring serum levels in severe infections.
PHOXILLUM B22K 4/0 is a bicarbonate-buffered, low-calcium dialysate for continuous renal replacement therapy (CRRT). Monitor serum potassium closely as it contains 4 m Eq/L K+, 0 m Eq/L Ca2+, and 22 m Eq/L bicarbonate. Use with caution in hyperkalemic patients; may require adjustment of potassium supplementation. Ensure adequate calcium replacement via separate infusion to avoid hypocalcemia. Verify compatibility with other IV fluids and medications administered through the CRRT circuit.
AMCILL (ampicillin) is a broad-spectrum penicillinase-sensitive penicillin. Use caution in patients with renal impairment; dose adjustment required for Cr Cl <30 m L/min. Monitor for hypersensitivity reactions, especially in patients with cephalosporin allergy. IV administration may cause phlebitis; rotate infusion sites. Not effective against penicillinase-producing organisms including Staphylococcus aureus.
This solution is used only during continuous dialysis in the hospital setting; it is not for direct infusion into your vein.,Your healthcare team will monitor your blood potassium and calcium levels closely while you receive this treatment.,Do not eat or drink anything unless your doctor or nurse approves, as your diet may need to be adjusted.,Report any muscle cramps, tingling, or irregular heartbeat to your nurse immediately.
Take exactly as prescribed; complete full course even if you feel better.,Notify your doctor if you develop rash, hives, or difficulty breathing.,May cause diarrhea; contact your doctor if severe or bloody.,Take with a full glass of water; avoid acidic beverages like orange juice.,Inform your doctor if you are pregnant, breastfeeding, or taking oral contraceptives (ampicillin may reduce efficacy).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER vs AMCILL, answered by our medical review team.
PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER is a Irrigation Solution that works by PHOXILLUM B22K 4/0 is a peritoneal dialysis solution containing bicarbonate/lactate as buffer. It corrects electrolyte imbalances, removes waste products (e.g., urea, creatinine) via diffusion and ultrafiltration across the peritoneal membrane. Bicarbonate helps correct metabolic acidosis.. AMCILL is a Penicillin Antibiotic that works by Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER and AMCILL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER is: Intravenous infusion of 4 mmol/kg potassium phosphate per 24 hours, administered at a rate not exceeding 10 mmol/hour as part of total parenteral nutrition; typical adult dose: 30-40 mmol potassium phosphate per day.. The standard adult dose of AMCILL is: 250-500 mg orally every 8 hours or 500 mg every 12 hours; for severe infections, up to 1 g every 6 hours intravenously.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER and AMCILL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER is classified as Category C. No well-controlled studies in pregnant women. Animal reproduction studies not conducted. Potassium phosphate is essential for fetal development; however, hyperphosphatemia or elect. AMCILL is classified as Category C. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. First trimester: Not associated with major birth defects. Second and third trimesters: Use only if clearl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.